EN
EN
BioNova Submits Investigational New Drug Application for BN301 for the Treatment of Hematologic Malignancies in China
July 01, 2022

BioNova today announced that it has submitted an investigational new drug (IND) application for BN301 (STRO-001) for the treatment of hematologic malignancies to the China National Medical Products Administration (NMPA).